

Clinical Implementation of a Proton Therapy System

Jatinder R. Palta PhD
University of Florida



Acknowledgements

Clinical

Nancy Price
Mendenhall, MD
Robert Malyapa,
MD, Ph.D.
Sameer Keole, MD
Carlos Vargas, MD


Technical

Zuofeng Li, DSc
Daniel Yeung, PhD
Rolf Slopsema, MS
Stella Flampouri, PhD
Darren Kahler, PhD
Wen Hsi, PhD
George Zhao, PhD
Liyong Lin, PhD


Outline

- Overview of the University of Florida Proton Therapy Institute (UFPTI)
- Overview of clinical operations and work flow at UFPTI
- Review of a strategic and operational optimization model of Patient Scheduling
- Personal Observations

The University of Florida Proton Therapy Institute (UFPTI)




UFPTI Proton Area



- Integrated Facility Management
- Treatment Planning
- Patient Scheduling
- Treatment Control & Delivery

UFPTI Conventional and Simulation Area



UFPTI Equipment

- IBA Proteus 235 Proton Therapy System
 - 3 Gantry Treatment Rooms, 1 Eye Treatment Room
- Conventional Therapy Equipment
 - 2 Elekta Synergy LINACs with Camera Systems
- Simulation
 - Philips Big Bore CT, PET-CT, and 0.23 T open MR Scanners
- Treatment Planning
 - Varian Eclipse and Philips Pinnacle system for proton and conventional treatment planning respectively
- Facility Management System
 - IMPAC MOSAIQ

Proton Gantry and PPS

- Nozzle installed on gantry
- Snout installed in nozzle
- PPS: 6 degree-of-freedom isocentric motion
 - 50X50X50 cm³ treatable volume
 - +/- 3° ranges of pitch and roll corrections




Clinical Operations and Workflow

Carlos Vargas, Robert Malyapa, and Nancy Mendenhall; **Physicians**
 Zuofeng Li, Wen Hsi, and Daniel Yeung; **Physicists**
 Gary Barlow, Trevor Fleming Ernie St John; **Therapists**
 Debbie Louis and Craig McKenzie; **Dosimetrists**
 Stuart Klein; **Administrator**


Average Daily Treatments at UFPTI

(August, 2006- August 2008)



Hours of Operation: 6:00AM- 10:00 PM

Clinical Workflow



Need for Optimized Workflow in Proton Therapy

- Dose calculation and delivery of proton therapy is highly sensitive to various sources of uncertainties
 - CT HU –stopping power conversion
 - Increased RBE at distal falloff region of SOBP
 - Dose calculation uncertainties
 - Physiological changes
 - High-Z metal implant artifacts
 - Organ motion
 - Tumor regression or progression


Proton Therapy Workflow

- Patient selection for proton therapy performed in *Proton Therapy Patient Disposition Conference* for new disease sites or patients that may require special considerations in simulation, planning, and delivery techniques

```
graph TD; A[Patient Referral] --> B[New Patient Consultation]; B --> C[Clinical evaluation]; B --> D[Technical evaluation]; C --> E{Treatment modality?}; D --> E; E --> F[Conventional radiotherapy]; E --> G[Proton therapy]; F --> H[Patient Diagnostic Workup]; G --> I[Simulation];
```

The flowchart illustrates the Proton Therapy Workflow. It begins with 'Patient Referral', leading to 'New Patient Consultation'. From there, the process splits into 'Clinical evaluation' and 'Technical evaluation'. Both lead to a decision point 'Treatment modality?'. If 'Conventional radiotherapy' is chosen, the next step is 'Patient Diagnostic Workup'. If 'Proton therapy' is chosen, the next step is 'Simulation'.

- Patient selection for proton therapy performed in *Proton Therapy Patient Disposition Conference* for new disease sites or patients that may require special considerations in simulation, planning, and delivery techniques




Proton Therapy Workflow

- CT HU – proton stopping power customized for scanning Field-of-View (FOV) between large bore and small bore CT scanners

```
graph TD; Simulation[Simulation] --> Setup{Setup Technique?}; Setup --> Immobilization[Site-dependent immobilization devices]; Immobilization --> Motion{Organ motion evaluation?}; Motion --> CTScan{CT scan technique?}; CTScan --> LargeBore[Large bore CT]; CTScan --> SmallBore[Small bore CT]; LargeBore --> Treatment[Treatment Planning]; SmallBore --> Treatment; Patient[Patient Diagnostic Workup] -.-> Treatment; CineMRI[Cine-MRI, 4D CT, ABC] -.-> Motion;
```

The flowchart illustrates the Proton Therapy Workflow. It begins with a yellow box labeled 'Simulation', which leads to a white diamond decision box 'Setup Technique?'. This leads to a white box 'Site-dependent immobilization devices', which leads to another white diamond decision box 'Organ motion evaluation?'. A yellow box 'Cine-MRI, 4D CT, ABC' has an arrow pointing to the 'Organ motion evaluation?' box. From 'Organ motion evaluation?', the flow goes to a white diamond decision box 'CT scan technique?'. This box branches into two white boxes: 'Large bore CT' and 'Small bore CT'. Both of these lead to a final yellow box 'Treatment Planning'. A yellow box 'Patient Diagnostic Workup' is connected to 'Treatment Planning' by a dashed line.

- CT HU – proton stopping power customized for scanning Field-of-View (FOV) between large bore and small bore CT scanners



Proton Therapy Workflow

```
graph TD; PW[Patient Diagnostic Workup] -.-> GTV[GT, CT, ITV delineation]; TP[Treatment Planning] --> GTV; GTV --> BPC[Beam parameter selection and dose calculation]; BPC --> U[Uncertainty evaluation]; U --> BPC; BPC --> PRA[Plan review and approval]; PRA --> BPC; PRA --> DDP[Delivery data and documentation preparation]; DDP --> ACF[Aperture and compensator fabrication]; ACF --> DDP; DDP --> PQA[Patient-specific QA tests]; PQA --> TD[Treatment Delivery]; GTV --> UOM[Use of organ motion data]; UOM --> BPC;
```


The diagram illustrates the Proton Therapy Workflow, a sequential process involving patient diagnostic workup, treatment planning, and delivery. Key components include:

- Patient Diagnostic Workup** (yellow box) connects via a dashed line to **GT, CT, ITV delineation** (white box).
- Treatment Planning** (yellow box) connects to **GT, CT, ITV delineation** (white box).
- GT, CT, ITV delineation** (white box) connects to **Beam parameter selection and dose calculation** (white box).
- Beam parameter selection and dose calculation** (white box) connects to **Uncertainty evaluation** (white box).
- Uncertainty evaluation** (white box) connects back to **Beam parameter selection and dose calculation** (white box).
- Beam parameter selection and dose calculation** (white box) connects to **Plan review and approval** (white box).
- Plan review and approval** (white box) connects back to **Beam parameter selection and dose calculation** (white box).
- Plan review and approval** (white box) connects to **Delivery data and documentation preparation** (white box).
- Delivery data and documentation preparation** (white box) connects to **Aperture and compensator fabrication** (white box).
- Aperture and compensator fabrication** (white box) connects back to **Delivery data and documentation preparation** (white box).
- Delivery data and documentation preparation** (white box) connects to **Patient-specific QA tests** (white box).
- Patient-specific QA tests** (white box) connects to **Treatment Delivery** (yellow box).
- Use of organ motion data** (yellow box) connects to **GT, CT, ITV delineation** (white box).

Key Considerations (Listed in a box on the left):

- Target delineation based on standard or in-house protocols
- Beam parameters selected with consideration of beam characteristics and organ motion data
- Plan reviewed with consideration of dose calculation and treatment delivery uncertainties

- Target delineation based on standard or in-house protocols
- Beam parameters selected with consideration of beam characteristics and organ motion data
- Plan reviewed with consideration of dose calculation and treatment delivery uncertainties




Proton Therapy Workflow

- Patient scheduling is constrained by
 - Need for anesthesia
 - Need for snout changes
 - Expected in-room time
 - Between-fraction time for BID treatments
- Motion monitoring action levels calculated from 4D CT or ABC scan data
- Tumor regression monitored by repeat imaging studies
- *Adaptive Proton Therapy*

```
graph TD; A[Treatment Delivery] --> B[Patient tx. room scheduling]; B --> C[Patient Setup]; C --> D{Organ motion?}; D -- Yes --> E[Motion monitoring and control]; E --> F{Tumor regression?}; D -- No --> F; F -- Yes --> G[Tumor regression dosimetry evaluation]; F -- No --> H[Completion of Treatment];
```

The flowchart illustrates the Proton Therapy Workflow. It begins with 'Treatment Delivery' (yellow box), leading to 'Patient tx. room scheduling' (white box), then 'Patient Setup' (white box). A decision diamond asks 'Organ motion?'. If 'Yes', it leads to 'Motion monitoring and control' (white box), which then leads to another decision diamond 'Tumor regression?'. If 'No' to 'Organ motion?', it also leads to 'Tumor regression?'. If 'Yes' to 'Tumor regression?', it leads to 'Tumor regression dosimetry evaluation' (white box). Finally, if 'No' to 'Tumor regression?', it leads to 'Completion of Treatment' (white box).

- Patient scheduling is constrained by
 - Need for anesthesia
 - Need for snout changes
 - Expected in-room time
 - Between-fraction time for BID treatments
- Motion monitoring action levels calculated from 4D CT or ABC scan data
- Tumor regression monitored by repeat imaging studies
- *Adaptive Proton Therapy*




Prostate Motion Monitoring

- A PTV margin was calculated to allow CTV coverage in 95% of treatments for 90% of patients (van Herk, IJROBP, 2000)
 - Assuming setup error bounded within ± 2 mm with daily orthogonal imaging and VisiCoil fiducial markers
 - Assuming prostate intra-fraction motion of 2 mm in 5 min
 - PTV margin = 4 mm axial and 6 mm cranial-caudal
 - *How to identify the 10% patients with larger intra-fraction prostate motion magnitude?*

Prostate Motion Monitoring

- Treatment Delivery Workflow Tasks:
 - Confirmation of appropriateness of PTV margin for *a specific patient* during treatment delivery
 - Selection of actions to take for *a specific patient* when intra-fraction motion magnitude is larger than assumption

Prostate Motion Monitoring



Results of Prostate Motion Monitoring

- For week of May 12, 2008 – May 16, 2008:
 - 181 Post-treatment DIPS image pairs taken
 - 10 of 181 with DIPS-calculated correction vectors larger than 4 mm axial or 6 mm cranial-caudal
 - 5.5 % of image pairs out of tolerance
 ➢ 9 % expected
 - *Prostate motion monitoring working as expected*

Curtsey Zuofeng Li DSc


Prostate Motion Monitoring and Control

- Actions to improve control and reduce dosimetric effect of prostate intra-fraction motion
 - Patient diet control
 - Additional saline in rectum
 - Use of rectal balloon
 - Increase aperture margin

Thoracic/Abdomen Organ Motion Evaluation




1. Perform 4D CT scan
2. If patient is candidate for use of ABC device, perform 3 ABC scans
3. Compare maximum target excursion between 4D CT scans and ABC scans to select technique to use
4. Calculate PTV margin and patient setup imaging tolerances



Treatment Planning for Thoracic and Abdomen Tumors


1. Use **average** 4D CT or ABC scans for ITV delineation
2. Override IGTV with tissue HU for thoracic tumor (Kang et al, IJROBP 2007)

1. Minimize weightings of beams with larger range uncertainties due to physiological changes
2. Use distal blocking for beams stopping near critical organs to reduce impact of range uncertainties and increased RBE
3. For patients receiving proton therapy as boost treatment following photon irradiation, constrain proton beam paths to within previous photon beam paths when possible




Thoracic and Abdomen Organ Motion Monitoring

1. For initial 3 days of treatments, perform DIPS imaging for each treatment field and calculate correction vectors
2. Inform physics if any field-specific correction value is larger than 5 mm (1 out of 3 expected)
 - Correction must be calculated from a suitable surrogate of target
3. If no correction vectors larger than 5 mm in first 3 days of treatment, perform no more field-specific DIPS imaging



- Between April 30, 2008 and May 15, 2008:
 - 36 field-specific DIPS images obtained
 - 1 image showed larger than 5 mm correction
 - 2.8 % of images out of tolerance
 - *More data needed for validation of hypothesis*
 - *Potential to reduce target margin*

- Patient receives, in alternate weeks, PET-CT activation study scans, or 4D CT/ABC scans as patient is treated
- 4D CT/ABC scans reviewed for tumor regression
 - Tumor regression models under development at UF
- Verification plan performed on new CT scans if significant dosimetric changes suspected

[illegible]

Outcome tracking protocol for Prostate

[illegible]

Base of Skull
Chordoma,
Chondrosarcoma,
and Cervical
Spine

[illegible]

Head and Neck

[illegible]

Intracranial Tumor

[illegible]

Dosimetry Check List

Unresectable
Pancreatic
Cancer

ID CT/Imaging Fusion checked: Physician: _____ Date: _____ Physician: _____ Date: _____
 (1) CT (2) MRI (3) PET (4) US (5) Other: _____

Contours checked: Physician: _____ Date: _____ Physician: _____ Date: _____

Normal Organs:

Esophagus: Liver ☐ LT Kidney ☐ ST Kidney ☐ Spinal Cord ☐
 LFT Lung ☐ RT Lung ☐ Ovary ☐
 Prostate: Stomach ☐ Small Bowel ☐ Colon ☐
 Targets: GTV ☐ CTV ☐ PTV ☐

Proton Field Arrangement: Physician: _____ Date: _____ Physician: _____ Date: _____
 Fid 1: _____ Fid 2: _____ Fid 3: _____ Fid 4: _____

Block margin: _____
Distal margin: _____
Post margin: _____

DOSE: Physician: _____ Date: _____ Physician: _____ Date: _____
 RTV 70%: 10280 ☐ YES ☐ NO RTV 100%: _____
 RTV Target V10%: 2547 ☐ YES ☐ NO 100%: _____

LT Kidney V20 Gy: _____ < 1390? ☐ YES ☐ NO RT Kidney V20 Gy: _____ < 1390? ☐ YES ☐ NO
 Liver V20 Gy: _____ < 1950? ☐ YES ☐ NO Liver V25 Gy: _____ < 1950? ☐ YES ☐ NO
 Small Bowel V45 Gy: _____ < 1950? ☐ YES ☐ NO Stomach V45 Gy: _____ < 1950? ☐ YES ☐ NO
 Max Spinal Cord < 45 Gy? ☐ YES ☐ NO

Chart: Physician: _____ Date: _____ Physician: _____ Date: _____
 Prescription signed: _____ Date: _____ Recd: _____ Date: _____ # of days: _____

Patient-Specific QA

- Verification of aperture and compensator geometries
 - Dosimetric properties verified as part of commissioning with regularly-shaped apertures and compensators
 - 1 mm tolerance
- Output model (*Kooy, 2003 & 2005*) commissioned for limited proton beam range and modulation combinations
 - Output measured for range and modulations outside commissioned model
 - Range verifier readings obtained for commissioned range and modulation combinations
 - Output measured for small field sizes
- Depth dose and profiles measured per physicist recommendations
 - Depth doses measured for first 5 uses of a sub-option
 - Dose profiles measured for each new disease site for first 5 patients

Strategic and Operational Optimization Model of Patient Scheduling for a Multi-Room Proton Therapy Facility

Edwin Romeijn and Ehsan Salari; **Industrial Engineers**
 Nancy Mendenhall; **Physician**
 Jatinder Palta and Zuofeng Li; **Physicists**
 Gary Barlow; **Therapists**
 Stuart Klein; **Administrator**

Project goals

- Analyzing the capacity of the center in treatment delivery
- Studying the effect of different scenarios on the capacity
- Investigating the potential capacity improvements
- Developing an operational algorithm to schedule individual patients for treatment

UFPTI specifications

- Number of gantry rooms: 3 gantries
- Capacity of each gantry: 15 hours/day
- New patients' treatment starting day: Monday–Wednesday
- New patient's treatment starting time: 7 am – 4 pm
- Minimum time between fractions for B.I.D patients: 6 hours
- Snout changing time: 15 minutes
- Anesthesia team availability: 4 hours/day on a single gantry
- Gantry switches are not allowed during the treatment.
- Gantry 3 is specialized to 1-field prostate patients.

Patient Categories and Patient Mix

Category	Anesthesia (Y/N)	Time/fraction (min)	# fractions	# fractions /day	Add. 1 st Fraction (min)	Snout size	Current mix (%)	Comment
1	N	18	40	1	15	18	65	1-Field Prostate
2	N	30	40	1	15	18	15	2-Field Prostate
3	N	35	62	2	20	18	7	H&N/BOS
4	N	45	62	2	25	25	3	Thorax/Abdomen chordomas
5	N	35	30	1	20	10	3	Simple Brain
6	Y	55	30	1	20	18	2	Peds Brain with Anesthesia
7	N	60	30	1	45	25	1	CSI no Anesthesia
8	Y	90	30	1	45	25	1	CSI with Anesthesia
9	N	50	42	1	30	18	2	Lung/Abdomen with ABC/Body FIX
10	N	35	12	1	20	18	1	Concomitant Boost Patients

Strategic-level model

Objective function:

- Maximizing number of fractions delivered per day
- Minimizing deviation from the desired patient mix
- Maximizing number of pediatrics patients treated

Constraints:

- Patients' treatment continuity
- Gantry capacity
- Constraints on
 - Starting day for new patients
 - Starting time for new patients during a day
 - Anesthesia team availability
 - Minimum time between fractions for B.I.D patients
- Gantry specialization
- Gantry switching (allowed/not allowed)

Strategic-level model

Other Considerations

- treatment time/fraction reduction
 - Category1: 3min; Category2: 2min; Category6: 15 min; Category7: 15 min; Category8: 30 min
- Saturday start for prostate cases (categories1 and 2)
- No gantry specification/ no gantry switching
- Gantry capacity variability: reducing gantry availability on Thu-Fri while extending the availability on Mon-Wed
- Vary patient mix

Modeling and Solution Approach

- Modeling approach:
 - A Mixed-Integer-Programming model has been developed based on these objective functions and constraints.
 - This model is a cyclic one assuming the system is in steady state.
- Solution approach:
 - The model is implemented in Cplex and solved close to optimality using Branch & Bound techniques.

Sensitivity analysis

Studying the effect of:

- Allowing gantry switches during treatment
- Reducing snout changing time
- Specializing a gantry for a certain category
- Reducing the treatment time/fraction for some categories
- Changing the desired patient mix
- Extending the anesthesia team's availability
- Extending gantries' working hours
- Saturday start for prostate patients
- Increasing the average number of fractions delivered per day

on:

- Average daily number of fractions delivered
- Performance measures (resource utilization and set-up time)
- Treated patient mix

Results

Patient mix scenarios

Scenario	C1	C2	C4	C4	C5	C6	C7	C8	C9	C10
Ideal	49	11	14	6	6	4	2	2	4	2
Basic	65	15	7	3	3	2	1	1	2	1

Daily capacity and utilization

Scenario	Average frac./day	Gantry 1 utilization	Gantry 2 utilization	Gantry 3 utilization
Ideal	82	96	87	84
Basic	100	96	93	97

Studying the effect of extending the anesthesia team availability (an example)

Categories	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
Desired patient mix	TBD	15	7	3	3	TBD	1	TBD	2	1
1 x 4	66.5	16.4	5.7	1.7	1.7	2.3	0.6	2.3	1.7	1.1
1 x 5	65.3	15.9	5.1	2.8	1.2	2.8	1.2	2.8	1.7	1.2
2 x 6	64.1	11.6	6.1	0	2.2	6.6	1.1	6.6	1.1	0.6

Desired patient mix vs. the solution patient mix

Performance measures	G1 %	G2 %	G3 %	Average # ped/day	Average # tx/day
1 x 4	91	90	93	3.7	110.1
1 x 5	96	92	93	4.6	110.1
2 x 6	95	97	96	11	110.1

Performance measures for different scenarios

Strategic Model Conclusions

- With the treatment time/fraction reduction of :
 - *Category 1: 3min; Category 2: 2min; Category 6: 15 min; Category 7: 15 min; Category 8: 30 min*
 - Can treat up to **15** pediatric patients per day
 - Treat up to a maximum of **135** fractions per day (**30,000** fractions per year)
- **Concerns:**
 - The optimal patient mix with respect to pediatric patients consists largely of Category 6 cases
 - The optimal patient mix with respect to other patients consists largely of single-field prostate cases

Summary and Personal Observations

- Proton therapy differs significantly from conventional radiotherapy in its higher sensitivity to various sources of uncertainties
 - **What you see is not what you get**
- Disease-site-specific clinical workflow must be designed to address the dosimetric effects of these uncertainties
 - **Even then some patients may have to be treated with modalities other than protons**
- These workflow modifications may require increased efforts compared to their conventional therapy counterparts, but are necessary to optimize proton therapy treatments
 - **It is highly unlikely that we will realize greater efficiency in clinical operation of PTS compared to conventional radiation therapy**